HIV / AIDS – GCC Nurse Clinical Guide

Overview

Staging & CD4

ART Treatment

Opportunistic Infections

GCC Context

MCQ Practice

🔬 HIV Pathophysiology

HIV (Human Immunodeficiency Virus) is a retrovirus that primarily infects CD4⁺ T-lymphocytes (T-helper cells), progressively destroying the immune system. Without treatment, it leads to AIDS (Acquired Immunodeficiency Syndrome).

Transmission Routes

Unprotected sexual intercourse (anal highest risk)
Sharing injection drug equipment
Mother-to-child (perinatal, breastfeeding)
Blood transfusion / organ transplant (now rare with screening)
Needlestick injury (occupational)
NOT transmitted by: casual contact, coughing, toilet seats, sharing food

Acute HIV Infection (Seroconversion Illness)

2–4 weeks post-exposure
Fever, lymphadenopathy, pharyngitis, rash (maculopapular), myalgia, headache
Resembles infectious mononucleosis
Very high viral load — highly infectious
Resolves spontaneously in 2–4 weeks

Natural History of HIV

Acute infection / seroconversion illness: 2–4 weeks post-exposure; high viral load; symptomatic or asymptomatic
Clinical latency / chronic HIV: Months to years; low/no symptoms; CD4 count slowly declining; still infectious
AIDS: CD4 count <200 cells/µL OR AIDS-defining illness; opportunistic infections and cancers emerge

Diagnosis

4th generation HIV test (antigen/antibody combination test): Detects HIV p24 antigen AND HIV antibodies; can detect HIV from 18 days post-exposure; standard initial test
Window period: 4th generation: 18–45 days; older 3rd gen antibody tests: up to 90 days
HIV RNA PCR (viral load): Most sensitive; detects HIV from 7–10 days; used in acute infection, indeterminate results, monitoring
Confirmatory western blot or supplemental test after reactive initial test

"Undetectable = Untransmittable" (U=U): A person with HIV on effective ART with a sustained undetectable viral load CANNOT sexually transmit HIV to a partner. This is now WHO-endorsed scientific consensus.

📊 HIV Staging — WHO and CDC

CD4 Count — The Immune Gauge

CD4 Count (cells/µL)	Interpretation	Risk
>500	Normal range	Low risk of OIs
200–500	Moderate immunosuppression	TB, bacterial infections
<200	Severe immunosuppression (AIDS threshold)	PCP, Toxoplasma, Cryptococcus
<50	Profound immunosuppression	CMV, MAC, PML, Cryptosporidium

WHO Clinical Staging (1–4)

Stage	Features	CD4 Guidance
1	Asymptomatic; persistent generalised lymphadenopathy	Usually >500
2	Mild weight loss (<10%), minor mucocutaneous problems (herpes zoster, oral candida, recurrent URTIs)	350–500
3	Severe weight loss (>10%), chronic diarrhoea, pulmonary TB, recurrent bacterial pneumonia, oral candidiasis	200–350
4 = AIDS	AIDS-defining conditions: PCP, CMV retinitis, Cryptococcal meningitis, Toxoplasma encephalitis, HIV wasting, Kaposi's sarcoma, lymphoma	<200

AIDS-Defining Conditions (Selected)

Infections (OIs)

Pneumocystis jirovecii pneumonia (PCP) — CD4 <200
Cerebral toxoplasmosis — CD4 <100
Cryptococcal meningitis — CD4 <100
CMV retinitis — CD4 <50
MAC (Mycobacterium avium complex) — CD4 <50
Extrapulmonary TB
Cryptosporidiosis (chronic diarrhoea)

Malignancies

Kaposi's sarcoma (HHV-8) — violaceous skin/mucosal lesions
High-grade B-cell lymphoma (non-Hodgkin)
Primary CNS lymphoma (EBV-related)
Invasive cervical cancer (HPV-related)

💊 Antiretroviral Therapy (ART)

ART recommended for ALL people living with HIV regardless of CD4 count. Early treatment reduces transmission, preserves immune function, and prevents AIDS complications. Goal: undetectable viral load (<50 copies/mL) within 6 months.

Main ART Drug Classes

Class	Abbreviation	Examples	Target
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors	NRTI	Tenofovir (TDF/TAF), Emtricitabine (FTC), Lamivudine (3TC), Abacavir (ABC)	Blocks reverse transcriptase (RNA→DNA)
Non-Nucleoside Reverse Transcriptase Inhibitors	NNRTI	Efavirenz, Rilpivirine, Doravirine	Blocks reverse transcriptase (different site)
Integrase Strand Transfer Inhibitors	INSTI	Dolutegravir, Bictegravir, Raltegravir	Prevents viral DNA integration into host genome
Protease Inhibitors	PI	Darunavir, Atazanavir (with ritonavir boost)	Prevents viral protein assembly
CCR5 Antagonist	—	Maraviroc	Blocks CCR5 co-receptor entry

First-Line Regimen (2024 WHO)

Preferred first-line: Dolutegravir (INSTI) + Tenofovir (TDF or TAF) + Emtricitabine or Lamivudine
Fixed-dose combination: Bictegravir/TAF/FTC (Biktarvy) — once daily, single pill, high barrier to resistance
Alternative: Dolutegravir/3TC dual therapy for selected patients

PEP — Post-Exposure Prophylaxis

PEP must be started within 72 hours of exposure. The sooner the better — ideally within 2 hours. PEP after 72 hours has no proven benefit.

Recommended for: significant occupational exposure (needlestick), sexual assault, high-risk sexual exposure
Regimen: Tenofovir/Emtricitabine + Dolutegravir (or Raltegravir) for 28 days
HIV test at baseline (before starting), 4 weeks, and 12 weeks
Efficacy: ~80% effective if started promptly and completed

PrEP — Pre-Exposure Prophylaxis

PrEP: Tenofovir/Emtricitabine (Truvada) or Tenofovir alafenamide/FTC (Descovy) taken daily by HIV-negative people at high risk — reduces HIV acquisition risk by >99% with perfect adherence.

Indicated for: high-risk heterosexual partners of HIV+ person, men who have sex with men (MSM), IV drug users
Monitor: HIV test every 3 months, renal function (TDF nephrotoxicity)
Newer injectable PrEP: Cabotegravir long-acting injection every 2 months

Nursing Considerations for ART

Adherence counselling — ART is lifelong; missed doses risk resistance development
Monitor viral load (every 3–6 months) and CD4 count (every 6–12 months)
Common side effects: GI upset (nausea with first dose), headache, fatigue — usually resolve in 2–4 weeks
Tenofovir: monitor renal function and bone density
Efavirenz: vivid dreams, neuropsychiatric effects — take at bedtime
Drug interactions: rifampicin (TB treatment) significantly reduces ART levels — use rifabutin instead or dose-adjust dolutegravir

🦠 Key Opportunistic Infections

1. PCP (Pneumocystis jirovecii Pneumonia) — CD4 <200

Presentation: progressive dyspnoea, dry cough, fever, hypoxaemia disproportionate to CXR findings
CXR: bilateral perihilar interstitial infiltrates ("bat wing" pattern) or normal
Treatment: Co-trimoxazole (TMP-SMX) high-dose × 21 days + prednisolone if PaO₂ <70 mmHg
Prophylaxis: Co-trimoxazole when CD4 <200
LDH elevated in PCP — useful biomarker

2. Cerebral Toxoplasmosis — CD4 <100

Presentation: focal neurological deficit, headache, seizures, fever; multiple ring-enhancing lesions on MRI with mass effect
Treatment: Pyrimethamine + Sulfadiazine + Folinic acid (or co-trimoxazole as alternative) × 6 weeks
Prophylaxis: Co-trimoxazole when CD4 <100 and Toxoplasma IgG positive

3. Cryptococcal Meningitis — CD4 <100

Presentation: subacute meningitis, headache, fever, often minimal meningism; raised ICP is major complication
Diagnosis: India ink stain of CSF (visible encapsulated yeast), cryptococcal antigen (CrAg), CSF culture
Treatment: IV Amphotericin B + Flucytosine induction (2 weeks) → oral Fluconazole consolidation
Raised ICP management: repeated lumbar punctures to drain CSF (therapeutic LPs)

4. CMV Retinitis — CD4 <50

Presentation: painless progressive visual loss, floaters, "pizza pie" retinal appearance (haemorrhages + exudates)
Treatment: IV/oral Ganciclovir or Valganciclovir; intravitreal ganciclovir implants
Urgent ophthalmology referral — can cause permanent blindness if untreated

5. TB in HIV

TB is the most common cause of death in HIV-positive patients globally
GCC context: high TB incidence in South Asian and African migrant workers
Extrapulmonary TB (lymph nodes, bone, CNS) more common with advanced HIV
ART + TB treatment: complex drug interactions (rifampicin + ART) — specialist management
IRIS (Immune Reconstitution Inflammatory Syndrome): paradoxical worsening when ART started, immune system reactivates against pathogens

Immune Reconstitution Inflammatory Syndrome (IRIS): Occurs in first 4–8 weeks of ART. Inflammatory response to previously subclinical infections (TB, Cryptococcus, CMV). Manage with NSAIDs; steroids for severe cases. Do NOT stop ART.

🌍 GCC-Specific Context

HIV in the GCC — Epidemiology ▼

GCC countries have relatively low but rising HIV prevalence compared to global burden
Estimated HIV prevalence: <0.1% in most GCC countries (KSA, UAE, Qatar, Kuwait, Bahrain, Oman)
However: significant under-reporting due to stigma, criminalisation of transmission, deportation concerns
Predominant transmission routes in GCC: heterosexual (including from infected partners in endemic regions), intravenous drug use, and increasingly men who have sex with men (MSM — though illegal in GCC)
Migrant workers from Sub-Saharan Africa and South Asia (where HIV prevalence is higher) are a vulnerable population in the GCC
Mandatory HIV testing for residency visas/work permits in most GCC countries — HIV-positive individuals typically deported

Occupational HIV Exposure (Needlestick) in GCC ▼

Healthcare workers in GCC hospitals are at risk of occupational HIV exposure through needlestick injuries
All GCC hospitals have written needlestick protocols — report immediately to occupational health
PEP must be started within 72 hours — hospitals should have a 24/7 PEP starter pack available
Risk of HIV transmission from single needlestick from HIV+ source: ~0.3% (hollow-bore needle, deep injury = higher risk)
Safe sharps disposal (sharps bins, one-hand recapping technique or safety needles) is mandatory
International nursing staff working in GCC should be aware of local PEP protocols and report incidents promptly

HIV Stigma and Patient Confidentiality in GCC ▼

HIV carries significant stigma in GCC societies — cultural, religious, and legal dimensions
Healthcare workers have a strict duty of confidentiality — HIV status must NOT be disclosed without patient consent
Nurses must maintain professional boundaries: non-judgmental, compassionate care regardless of transmission route
Some patients may be unwilling to disclose HIV status due to fear of deportation — this creates healthcare access barriers
International nursing codes (ICN, NMC, NCLEX ethical framework) and GCC nursing regulations require confidentiality and non-discrimination
Islamic bioethical perspective: confidentiality in healthcare is supported; compassionate treatment of the sick is a religious duty

SCFHS / DHA / QCHP Exam Focus ▼

HIV infects CD4⁺ T-helper cells; AIDS = CD4 <200 OR AIDS-defining illness
Seroconversion illness: 2–4 weeks post-exposure; resembles mononucleosis
4th generation HIV test: detects antigen AND antibody; window period ~18–45 days
PEP: must start within 72 hours; TDF/FTC + dolutegravir × 28 days
PCP: CD4 <200; co-trimoxazole treatment; add steroids if PaO₂ <70 mmHg
Cryptococcal meningitis: India ink + CrAg; treat with Amphotericin B + Flucytosine
Cerebral toxoplasmosis: ring-enhancing lesions on MRI; pyrimethamine + sulfadiazine
IRIS: paradoxical worsening on ART initiation; do NOT stop ART
U=U: undetectable viral load = untransmittable (WHO-endorsed)

📝 MCQ Practice

1. A 32-year-old patient presents with 3 weeks of progressive dry cough, worsening dyspnoea, and fever. CXR shows bilateral perihilar infiltrates. HIV test is reactive with CD4 count 85 cells/µL. PaO₂ on room air is 62 mmHg. What is the MOST likely diagnosis and what treatment should be added to TMP-SMX?

✅ C — Classic PCP presentation: CD4 <200 (here 85), dry cough, bilateral infiltrates, hypoxaemia disproportionate to CXR findings. TMP-SMX is first-line treatment. Adjunctive corticosteroids (prednisolone) are indicated when PaO₂ <70 mmHg (9.3 kPa) as they reduce mortality by decreasing inflammatory lung injury.

2. A nurse sustains a deep needlestick injury from a hollow-bore needle used on an HIV-positive patient. When should PEP be started?

✅ B — PEP must be initiated ASAP after exposure — ideally within 2 hours, and definitely within 72 hours. PEP started after 72 hours has no proven benefit. Do NOT wait for HIV test results on the source patient if they are known HIV-positive — start PEP immediately and reassess.

3. An HIV-positive patient starts ART with CD4 40 cells/µL. After 3 weeks, they develop fever, worsening lymphadenopathy, and new pulmonary infiltrates. What is the MOST likely explanation?

✅ C — IRIS occurs in the first 4–8 weeks of ART as the recovering immune system mounts an exaggerated inflammatory response against previously subclinical infections (e.g., TB, Cryptococcus, MAC). Management: NSAIDs for mild cases; steroids for severe cases. Do NOT stop ART.

4. What does the statement "Undetectable = Untransmittable (U=U)" mean for clinical practice?

✅ C — U=U is WHO-endorsed scientific consensus from the PARTNER and HPTN 052 trials. A person with HIV maintaining an undetectable viral load (<200 copies/mL) on ART has effectively zero risk of sexually transmitting HIV. This is important for patient counselling, reducing stigma, and supporting adherence. ART must be continued — stopping treatment causes viral rebound.